α'-Methyletonitazene

α'-Methyletonitazene
Identifiers
  • N,N-diethyl-2-{2-[1-(4-ethoxyphenyl)ethyl]-5-nitro-1H-1,3-benzimidazol-1-yl}ethan-1-amine
Chemical and physical data
FormulaC23H30N4O3
Molar mass410.518 g·mol−1
3D model (JSmol)
  • CC(c1nc2cc(ccc2n1CCN(CC)CC)[N+](=O)[O-])c1ccc(OCC)cc1
  • InChI=1S/C23H30N4O3/c1-5-25(6-2)14-15-26-22-13-10-19(27(28)29)16-21(22)24-23(26)17(4)18-8-11-20(12-9-18)30-7-3/h8-13,16-17H,5-7,14-15H2,1-4H3
  • Key:DCJZWHORRZCIKH-UHFFFAOYSA-N

α'-Methyletonitazene is a benzimidazole derivative which is an opioid designer drug. It was the most potent compound identified in a series of etonitazene analogues tested for structure-activity relationship studies on this emerging class of designer drugs, though was still slightly less potent than etonitazene itself.[1][2][3]

See also

References

  1. ^ Vandeputte MM, Glatfelter GC, Walther D, Layle NK, St Germaine DM, Ujváry I, et al. (December 2024). "Characterization of novel nitazene recreational drugs: Insights into their risk potential from in vitro μ-opioid receptor assays and in vivo behavioral studies in mice". Pharmacological Research. 210 107503. doi:10.1016/j.phrs.2024.107503. PMC 11655282. PMID 39521025.
  2. ^ Vandeputte MM, Stove CP (2025). "Navigating nitazenes: A pharmacological and toxicological overview of new synthetic opioids with a 2-benzylbenzimidazole core". Neuropharmacology. 275 110470. doi:10.1016/j.neuropharm.2025.110470. PMID 40252758.
  3. ^ Stove CP, Vandeputte MM, Glatfelter GC, Walther D, Layle NK, St Germaine DM, et al. (2025). "Nitazenes of the Past, Present, and Future: Insights from in Vitro µ-opioid Receptor Assays and in Vivo Behavioral Studies in Mice (Abstract ID: 162711)". The Journal of Pharmacology and Experimental Therapeutics. 392 (3) 101052. doi:10.1016/j.jpet.2024.101052.